FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number	3235-02									

287 Estimated average burden hours per response: 0.5

## Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					or	Section	n 30(ł	n) of th	e Invest	ment (	Company Act	of 1940							
1. Name and Address of Reporting Person*  MUELLER PETER						2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [ VRTX ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  Officer (give title Other (specify					
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE					06	/16/20	)14				nth/Day/Year)	6	X Officer (give title Officer (specify below)  EVP, Global R&D, CSO  6. Individual or Joint/Group Filing (Check Applicable						
(Street)	N M	A	02210	)	_	4. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person  Form filed by More than One Reporting Person												son	
(City)	(S	•	(Zip)																
Table I - Non-Derive  1. Title of Security (Instr. 3)  2. Transactio Date (Month/Day/N				ion	n 2A. Deemed Execution Date,		3. 4. Securi		4. Securities	I of, or Beneficia es Acquired (A) or Of (D) (Instr. 3, 4 and 5)		5. Amou Securiti Benefici Owned I	5. Amount of Securities Beneficially Owned Following Reported		Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount	(A) or (D)	Price	Transac (Instr. 3	tion(s)			(Instr. 4)	
Common Stock 06/16/202				014				M		7,500	A	\$32.1	6 151	,017		D			
Common Stock 06/16/202				014	14			S <sup>(1)</sup>		4,403	D	\$67.72	146,614		D				
Common Stock 06/10				06/16/2	014	14			S <sup>(1)</sup>		1,500	D	\$68.25	3)(4) 145	5,114		D		
Common Stock 06/16/201					014	.4			S <sup>(1)</sup>		597	D	\$69.54	3)(5) 144	144,517		D		
Common Stock 06/16/201					014	.4			S <sup>(1)</sup>		1,000	D	\$70.29	3)(6) 143	143,517		D		
Common Stock														4,	770		I	401(k)	
Common Stock														5,	568			Revocable Trust	
Common Stock													15	15,233		I	Common stock held in trust <sup>(7)</sup>		
		٦	able								sposed of , converti			ly Owned )		•			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execu if any	eemed Ition Date, h/Day/Year)	4. Transa Code ( 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)				ate	7. Title a Amount Securiti Underly Derivati (Instr. 3	of es ing ve Securit	8. Price of Derivative Security (Instr. 5)		re es ally eg d tion(s)	10. Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership t (Instr. 4)	
					Code	v	(A)	(D)	Date Exerc	isable	Expiration Date	Title	Amoun or Numbe of Shares	er					
Stock Option (right to buy)	\$32.16	06/16/2014			М			7,500	(3	B)	07/23/2018	Commo Stock	<sup>n</sup> 7,500	\$0.00 \$0.00		,500 D			
£xplanatio	n of Respons	ses:																	

- 1. Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1.
- 2. Open market sales reported on this line occurred at a weighted average price of \$67.72 (range \$67.47 to \$67.96).
- 3. Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- $4. \ Open \ market \ sales \ reported \ on \ this \ line \ occurred \ at \ a \ weighted \ average \ price \ of \$68.25 \ (range \$68.04 \ to \$68.86).$
- $5. \ Open \ market \ sales \ reported \ on \ this \ line \ occurred \ at \ a \ weighted \ average \ price \ of \$69.54 \ (range \$69.15 \ to \$69.95).$
- 6. Open market sales reported on this line occurred at a weighted average price of \$70.29 (range \$70.00 to \$70.99).
- 7. Common stock held in grantor retained annuity trust.
- 8. Fully vested.

## Remarks:

Kenneth L. Horton, Attorney-In-Fact

06/18/2014

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.